Cell membrane derived liposomes loaded with DNase I target neutrophil extracellular traps which inhibits colorectal cancer liver metastases

Wang, Zhaozhong; Chen, Chen; Shi, Chongdeng; Zhao, Xiaotian; Gao, Lin; Guo, Feiyue; Han, Maosen; Yang, Zhenmei; Zhang, Jing; Tang, Chunwei; Zhang, Cai; Liu, Ying; Sun, Peng; Jiang, Xinyi

doi:10.1016/j.jconrel.2023.04.013

Cited by 9 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the deposition and light‐controlled cargo release from systemic delivery of AuPB@mPDA carriers in livers, abolishes NETs‐based capture of CTCs as well as metastatic spread. Cell membrane derived liposomes encapsulated with DNase I efficiently recruit neutrophils and eliminate NETs, eventually hindering CRC liver metastases 174 . Doxorubicin‐loaded micellar low‐molecular‐weight‐heparin‐astaxanthin nanoparticles decrease the recruitment of neutrophils in livers and MDSCs in lungs and breast tumors and suppress NF‐κB‐STAT3 signaling, thus preventing breast cancer hepatic metastasis via suppressing NETs formation as well as suppressing pulmonary metastasis and alleviating the inflammatory and immunosuppressive TME 175 .…”

Section: Emerging Nanoplatforms For Improving the Efficacy Of Antinet...mentioning

confidence: 99%

NETosis: Sculpting tumor metastasis and immunotherapy

Hu,

Wang,

Liu

2023

Immunological Reviews

View full text Add to dashboard Cite

SummaryThe process of neutrophil extracellular traps (NETs) formation, called NETosis, is a peculiar death modality of neutrophils, which was first observed as an immune response against bacterial infection. However, recent work has revealed the unique biology of NETosis in facilitating tumor metastatic process. Neutrophil extracellular traps released by the tumor microenvironment (TME) shield tumor cells from cytotoxic immunity, leading to impaired tumor clearance. Besides, tumor cells tapped by NETs enable to travel through vessels and subsequently seed distant organs. Targeted ablation of NETosis has been proven to be beneficial in potentiating the efficacy of cancer immunotherapy in the metastatic settings. This review outlines the impact of NETosis at almost all stages of tumor metastasis. Furthermore, understanding the multifaceted interplay between NETosis and the TME components is crucial for supporting the rational development of highly effective combination immunotherapeutic strategies with anti‐NETosis for patients with metastatic disease.

show abstract

Section: Emerging Nanoplatforms For Improving the Efficacy Of Antinet...mentioning

confidence: 99%

NETosis: Sculpting tumor metastasis and immunotherapy

Hu,

Wang,

Liu

2023

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…After ischemic nerve injury, a number of cytokines and damage associated molecular patterns (DAMPs) which induce the recruitment of neutrophils from peripheral circulation at cerebral ischemia areas and activate neutrophil-associated proinflammatory molecules expression, are widely released at the inflammation site. − Activated neutrophils release neutrophil extracellular traps (NETs) that are mainly composed of double-stranded DNA (dsDNA), histone, myeloperoxidase (MPO), cathepsin G, and neutrophil elastase (NE). − The presence of NETs has been found in the brain of ischemic stroke patients and in MCAO mice. , NETs disrupt the blood–brain barrier and promote thrombosis, which accounts for subsequent surrounding neurons injury and neurological disorders . The compromised BBB caused by ischemic stroke can promote the infiltration of immune cells into the injured brain, including neutrophils further aggravating the BBB disruption by secreting proinflammatory cytokines. − Therefore, inhibiting NET formulation in stroke lesions is a promising therapeutic target for ischemic stroke treatment …”

Section: Introductionmentioning

confidence: 99%

Smart Liposomal Nanocarrier Enhanced the Treatment of Ischemic Stroke through Neutrophil Extracellular Traps and Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase-Stimulator of Interferon Genes (cGAS-STING) Pathway Inhibition of Ischemic Penumbra

Sun,

Lv,

et al. 2023

ACS Nano

View full text Add to dashboard Cite

Brain inflammation is regarded as one of the leading causes that aggravates secondary brain injury and hinders the prognosis of ischemic stroke. After ischemic stroke, high quantities of peripheral neutrophils are recruited to brain lesions and release neutrophil extracellular traps (NETs), leading to the aggravation of blood−brain barrier (BBB) damage, activation of microglia, and ultimate neuronal death. Herein, a smart multifunctional delivery system has been developed to regulate immune disorders in the ischemic brain. Briefly, Cl-amidine, an inhibitor of peptidylarginine deiminase 4 (PAD4), is encapsulated into self-assembled liposomal nanocarriers (C-Lipo/CA) that are modified by reactive oxygen species (ROS)-responsive polymers and fibrin-binding peptide to achieve targeting ischemic lesions and stimuli-responsive release of a drug. In the mouse model of cerebral artery occlusion/reperfusion (MCAO), C-Lipo/CA can suppress the NETs release process (NETosis) and further inhibit the cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway in an ischemic brain. In addition, MCAO mice treated with C-Lipo/CA significantly mitigated ischemic and reperfusion injury, with a reduction in the area of cerebral infarction to 12.1%, compared with the saline group of about 46.7%. These results demonstrated that C-Lipo/CA, which integrated microglia regulation, BBB protection, and neuron survival, exerts a potential therapy strategy to maximize ameliorating the mortality of ischemic stroke.

show abstract

Engineering and Targeting Neutrophils for Cancer Therapy

Zhang,

Gu,

Wang

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Neutrophils are the most abundant white blood cells in the circulation and act as the first line of defense against infections. Increasing evidence suggests that neutrophils possess heterogeneous phenotypes and functional plasticity in human health and diseases, including cancer. Neutrophils play multifaceted roles in cancer development and progression, and an N1/N2 paradigm of neutrophils in cancer has been proposed, where N1 neutrophils exert anti‐tumor properties while N2 neutrophils display tumor‐supportive and immune‐suppressive functions. Selective activation of beneficial neutrophil population and targeted inhibition or re‐polarization of tumor‐promoting neutrophils has shown an important potential in tumor therapy. In addition, due to the natural inflammation‐responsive and physical barrier‐crossing abilities, neutrophils and their derivatives (membranes and extracellular vesicles) are regarded as advanced drug delivery carriers for enhanced tumor targeting and improved therapeutic efficacy. In this review, we comprehensively presented the recent advances in engineering neutrophils for drug delivery and targeting neutrophils for remodeling tumor microenvironment. This review will provide a broad understanding of the potential of neutrophils in cancer therapy.This article is protected by copyright. All rights reserved

show abstract

Cell membrane derived liposomes loaded with DNase I target neutrophil extracellular traps which inhibits colorectal cancer liver metastases

Cited by 9 publications

References 39 publications

NETosis: Sculpting tumor metastasis and immunotherapy

NETosis: Sculpting tumor metastasis and immunotherapy

Smart Liposomal Nanocarrier Enhanced the Treatment of Ischemic Stroke through Neutrophil Extracellular Traps and Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase-Stimulator of Interferon Genes (cGAS-STING) Pathway Inhibition of Ischemic Penumbra

Engineering and Targeting Neutrophils for Cancer Therapy

Contact Info

Product

Resources

About